Q2 2025 Earnings Forecast for Agios Pharmaceuticals, Inc. Issued By Zacks Research (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Analysts at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for Agios Pharmaceuticals in a note issued to investors on Wednesday, May 1st. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn ($1.62) per share for the quarter, up from their prior forecast of ($1.65). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($5.27) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q3 2025 earnings at ($1.56) EPS, Q4 2025 earnings at ($1.65) EPS, FY2025 earnings at ($6.49) EPS, Q1 2026 earnings at ($1.50) EPS and FY2026 earnings at ($5.31) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.20. The business had revenue of $8.19 million during the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The company’s revenue was up 46.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.47) earnings per share.

Other analysts also recently issued reports about the stock. Royal Bank of Canada dropped their target price on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating on the stock in a report on Friday, February 16th. The Goldman Sachs Group upped their price target on Agios Pharmaceuticals from $29.00 to $33.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. JPMorgan Chase & Co. reduced their price objective on Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating for the company in a research note on Friday, February 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, April 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $35.00.

Agios Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ AGIO opened at $32.80 on Monday. Agios Pharmaceuticals has a twelve month low of $19.80 and a twelve month high of $35.50. The firm has a 50-day moving average of $30.57 and a two-hundred day moving average of $25.84. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of -5.19 and a beta of 0.81.

Institutional Trading of Agios Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AGIO. China Universal Asset Management Co. Ltd. increased its stake in Agios Pharmaceuticals by 96.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,429 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 700 shares during the period. Quest Partners LLC purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at $41,000. Headlands Technologies LLC increased its stake in shares of Agios Pharmaceuticals by 31.3% in the third quarter. Headlands Technologies LLC now owns 9,037 shares of the biopharmaceutical company’s stock worth $224,000 after acquiring an additional 2,153 shares during the last quarter. NEOS Investment Management LLC purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $210,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Agios Pharmaceuticals by 25.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,502 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 2,148 shares during the last quarter.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 4,156 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $135,360.92. Following the transaction, the chief executive officer now directly owns 53,780 shares in the company, valued at approximately $1,751,614.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Brian Goff sold 4,156 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total value of $135,360.92. Following the completion of the sale, the chief executive officer now owns 53,780 shares of the company’s stock, valued at $1,751,614.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider James William Burns sold 2,642 shares of Agios Pharmaceuticals stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total value of $86,049.94. Following the transaction, the insider now owns 34,518 shares in the company, valued at approximately $1,124,251.26. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,035 shares of company stock worth $475,277. 4.24% of the stock is owned by corporate insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.